about
Echocardiographic imaging of procedural complications during balloon-expandable transcatheter aortic valve replacement.Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgeryPneumonia after cardiac surgery: Experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network.The Society of Thoracic Surgeons National Database 2016 Annual Report.Sex Differences in the Epidemiology of New-Onset In-Hospital Post-Coronary Artery Bypass Graft Surgery Atrial Fibrillation: A Large Multicenter Study.Impact of Preoperative Chronic Kidney Disease in 2,531 High-Risk and Inoperable Patients Undergoing Transcatheter Aortic Valve Replacement in the PARTNER Trial.One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis.Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis.Variation in Warfarin Use at Hospital Discharge After Isolated Bioprosthetic Mitral Valve Replacement: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database.Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis.Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral RegurgitationInitial Experience With Commercial Transcatheter Mitral Valve Repair in the United States.Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral RegurgitationIntroduction to the STS National Database Series: Outcomes Analysis, Quality Improvement, and Patient Safety.Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial.Costs associated with health care-associated infections in cardiac surgeryPredicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation.Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients.Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement.Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort--a analysis.Surgical treatment of moderate ischemic mitral regurgitation.The expanding role of mitral valve repair in triple valve operations: contemporary North American outcomes in 8,021 patients.Optimal surgical management of severe ischemic mitral regurgitation: to repair or to replace?The role of cardiovascular magnetic resonance in stratifying paravalvular leak severity after transcatheter aortic valve replacement: an observational outcome study.The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons score in the Placement of Aortic Transcatheter Valves trial.Does mitral valve repair offer an advantage over replacement in patients undergoing aortic valve replacement?Learning curves for transapical transcatheter aortic valve replacement in the PARTNER-I trial: Technical performance, success, and safety.Clinical Characteristics and Outcomes of Patients With Myocardial Infarction and Cardiogenic Shock Undergoing Coronary Artery Bypass Surgery: Data From The Society of Thoracic Surgeons National Database.Patients with type 2 diabetes undergoing coronary artery bypass graft surgery: predictors of outcomes.Impact of heparin-induced thrombocytopenia on postoperative outcomes after cardiac surgery.North American trial results at 1 year with the Sorin Freedom SOLO pericardial aortic valve.The medically managed patient with severe symptomatic aortic stenosis in the TAVR era: Patient characteristics, reasons for medical management, and quality of shared decision making at heart valve treatment centers.Preferential activation of SMAD1/5/8 on the fibrosa endothelium in calcified human aortic valves--association with low BMP antagonists and SMAD6Transcatheter versus surgical aortic-valve replacement in high-risk patients.Risk factors for conversion to cardiopulmonary bypass during off-pump coronary artery bypass surgery.The impact of specific preoperative organ dysfunction in patients undergoing aortic valve replacement.Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial.How to define a poor outcome after transcatheter aortic valve replacement: conceptual framework and empirical observations from the placement of aortic transcatheter valve (PARTNER) trialTrends in aortic clamp use during coronary artery bypass surgery: effect of aortic clamping strategies on neurologic outcomesChest wall resections and reconstruction: a 25-year experience.
P50
Q27310075-0C45F537-EFED-4AAC-8B13-6AA9003234C2Q28219200-43E3A6C3-D2F7-4963-B4FA-DFA212FE134CQ30252870-9FFFCC3E-18D4-4154-8250-32CAF2FCF321Q30275410-AB03DE5B-0D8A-4BC5-9400-33CF96485659Q30275685-167A6462-813B-4B16-8984-66A5F14C1C7BQ30276003-09A59C5C-702C-45C9-9DCE-AB176DD2154CQ30276378-937B4FAD-DC4F-4B4B-B54D-45B4F3D360F5Q30276791-2006B5CD-FB1E-4304-8918-4A92E07904FBQ30276890-4DA85BA4-59CF-4DA7-85F4-68EA9A159C88Q30277022-31D207C6-C876-41C2-92FC-602A4D5E26AEQ30277047-58E81658-9E44-411E-9E19-D18841C8EAC8Q30277169-7E330854-D9B5-40BD-AB29-0719C882B8F2Q30278369-8DCEBD81-876A-466C-9DF6-FE996C9B8636Q30278418-D28AD439-D3EA-45F1-87F4-800BA6336772Q30278907-43322F9B-F912-4D25-8282-E45E3738C78BQ30300984-A1A2F25F-79DF-421E-8F41-F7788766E896Q30301124-F5C2F5EA-3340-4768-8244-3E9D8FDB5B8AQ30301233-418DCF72-887A-44BF-8C52-4AB44EAB43D4Q30355931-399BB323-D7E5-45ED-AC03-511D0471B6CFQ30370788-A2AFAD48-17E9-41EB-99AF-19290121A2C4Q30389335-2AF360CE-1C08-4C9F-B297-1972D2D3CE1BQ30408054-B5FB5443-EBB9-4D09-933A-7EE3432EA905Q30412525-186F1E4A-6248-4AAA-ABFA-5C37C714103FQ30423461-462B76B8-4241-482F-B094-72DD6722F300Q30458103-18C7F80A-9295-434F-B865-B39078E9C764Q30458359-4D90E6CA-C375-45EF-83D1-EF898538B080Q30830148-4AE28185-7074-482F-BED5-AD3C94EDCBC5Q31034537-0BF4524F-199D-4509-9CAB-DD7F23BCEADCQ33338746-77C71910-B407-4F9B-A04C-830D8911EB45Q33377094-65C860AC-9BA3-4706-87A9-9391787F9AB6Q33423076-ACF47603-DD7B-4B47-96D4-7DCB3C695B6EQ33590311-FEA34035-44E6-42A9-925A-2481C453F6F4Q33941107-C80C302C-3692-49B4-8571-4B03A100E94FQ34189672-C6E8CF23-A838-41A5-8913-17802EB14E5FQ34268228-67DC5F53-7D26-4662-B5F6-B4E3B4FCA88DQ34318059-F3C90162-DC5D-478A-B03F-5C4A6E9FF815Q34343316-87BF9F12-9AFA-42CE-8787-CED493D92948Q34609578-74F1D8E3-0EBB-4B04-808B-5B404046FB6CQ34616117-028BB7BB-7488-4AA9-AD37-33F17538C1F3Q34700514-B58EF44A-39FA-4501-B263-5EBD7CF822DA
P50
name
Vinod H Thourani
@en
Vinod H Thourani
@nl
type
label
Vinod H Thourani
@en
Vinod H Thourani
@nl
prefLabel
Vinod H Thourani
@en
Vinod H Thourani
@nl